Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-11-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于第四届监事会第二十三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution passed at the 23rd meeting of the 4th Supervisory Board of the company, specifically regarding the approval of a stock option grant to incentive recipients. It details the meeting date, attendance, compliance with laws, and the decision to grant stock options. There is no financial report, earnings data, or detailed financial statements. The document is a formal announcement of a board/management decision related to stock option grants, which falls under management or board information. It is not an annual report, audit report, or earnings release. It is not a proxy solicitation or voting result announcement. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and focused on a board resolution, confirming this classification with high confidence.
2021-11-30 Chinese
可转换公司债券2021年付息公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the payment of interest on its convertible bonds (特一转债) for the year 2021. It details the bond code, interest rates, payment dates, tax information, and procedures for interest payment. The document does not contain financial statements or comprehensive financial performance data but focuses on the bond interest payment event. It is a formal notice about a capital/financing activity related to bond interest payment rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4422 characters, which is sufficient for a detailed announcement but not a full report. No indication of it being a report publication announcement or regulatory filing is present.
2021-11-29 Chinese
非公开发行股票发行情况报告书暨上市公告书（摘要）
Capital/Financing Update Classification · 100% confidence The document is a detailed report on a non-public stock issuance by 特一药业集团股份有限公司 (Teyi Pharmaceutical Group Co., Ltd.). It includes information on the number of shares issued, pricing, subscription details, regulatory approvals, investor information, and compliance with relevant securities regulations. The content focuses on the issuance process, subscription, allotment, and regulatory compliance related to a capital raising event through a non-public stock offering. There is no indication that this is an annual report, earnings release, or any other type of financial report. Instead, it is a comprehensive disclosure about a capital raising transaction, which fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is the report itself, not just an announcement or summary, so it is not RPA or RNS.
2021-11-28 Chinese
关于可转债转股价格调整的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 特一药业集团股份有限公司 regarding the adjustment of the convertible bond conversion price. It details the basis for the adjustment, the formula used, and the effective date of the new conversion price. The document is a formal disclosure about a change in the terms of convertible bonds, specifically the conversion price adjustment due to a non-public issuance of new shares. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. It is a regulatory announcement about a capital structure change related to convertible bonds. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (2003 characters), and it is not merely announcing the publication of a report but providing substantive information about the adjustment itself.
2021-11-28 Chinese
关于董事、监事、高级管理人员持股情况变动的报告
Director's Dealing Classification · 100% confidence The document is a report about changes in shareholdings of the company's directors, supervisors, and senior management following a non-public stock issuance. It details the shareholding quantities and percentages before and after the issuance for each individual. The document is titled as a report on shareholding changes of board members and senior management. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives. The document is short (1315 characters) and contains specific shareholding data, not a general announcement or a report publication notice. Therefore, the correct classification is DIRS.
2021-11-28 Chinese
关于董事会、监事会延期换届的提示性公告
Board/Management Information Classification · 100% confidence The document is a short announcement (606 characters) regarding the postponement of the board of directors and supervisory board re-election. It discusses the continuity of board and management duties and the delay in the election process. There is no financial data, no detailed report, no voting results, and no mention of an AGM meeting or presentation materials. The content clearly relates to management and board information, specifically about changes or delays in board/management terms. Therefore, the document fits best under 'Board/Management Information (MANG)'.
2021-11-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.